Related Experiment Videos
Influenza virosomes in vaccine development
Anke Huckriede1, Laura Bungener, Toos Daemen
1Department of Medical Microbiology, Molecular Virology Section, University of Groningen, 9713 AV Groningen, The Netherlands.
Methods in Enzymology
|January 13, 2004
Summary
Influenza virosomes, liposomes with viral spike proteins, effectively induce immune responses. Modifications to industrial production can enhance their potential as versatile vaccines against various diseases.
Area of Science:
- Immunology
- Vaccinology
- Biotechnology
Background:
- Influenza virosomes are liposomes displaying influenza virus spike proteins.
- They demonstrate immunogenicity, eliciting high antibody titers against influenza.
- Virosomes can present external antigens and possess intrinsic adjuvant properties.
Purpose of the Study:
- To explore the potential of influenza virosomes as vaccine carriers.
- To investigate their capacity for inducing humoral and cellular immune responses.
- To assess their applicability in developing vaccines against influenza, HIV, and cancer.
Main Methods:
- Reconstitution of influenza virus spike proteins (HA and NA) onto liposomes.
- Utilizing virosomes as antigen presentation systems for surface-associated or encapsulated antigens.
- Evaluating immune responses, including antibody formation, T-helper cell induction, and cytotoxic T-cell activation.
Main Results:
- Vaccination with influenza virosomes induces high levels of influenza-specific antibodies.
- Virosomes effectively support antibody and T-helper cell responses against surface-bound antigens.
- Retaining fusogenic properties of HA is crucial for eliciting cytotoxic T-cell responses.
Conclusions:
- Influenza virosomes are potent vaccine candidates with broad applicability.
- Current industrial production methods may compromise essential functional properties like fusion activity.
- Adaptations in production protocols are necessary to optimize virosome efficacy for diverse vaccine strategies.